Margaret Bradbury, PhD, has over 20 years of experience in drug discovery. After launching her pharmaceutical career at Merck Research Laboratories, Dr. Bradbury led pharmacology programs at Neurocrine Biosciences and was a Senior Director at Auspex Pharmaceuticals. At Teva Pharmaceuticals, she led multi-disciplinary studies integral for the discovery and approval of Austedo, a treatment for tardive dyskinesias and the chorea associated with Huntington’s disease.

Now at Alterity Therapeutics, Dr. Bradbury leads the nonclinical development program for ATH-434, a drug candidate for treatment of Parkinson’s disease, and leads research efforts for next generation metal-binding therapeutics. Dr. Bradbury has published and presented to a wide variety of audiences on several drug candidates.  She received her undergraduate degree from the University of Wisconsin-Madison and a PhD in neuroscience from the University of California-San Francisco. She also conducted postdoctoral research at Stanford University and the Salk Institute for Biological Research.